Expanding at a CAGR of 9.0%, the global mammalian derived proteins market is projected to increase from a valuation of USD 588.9 Million in 2021 to USD 1.5 Bn by 2032.
The increasing prevalence of cancer and fertility conditions among the population, and increasing adoption of hormonal therapies will attribute to the increase in the growth of the mammalian derived proteins market.
The proteins that are isolated from the mammalian system are known as mammalian derived proteins. These proteins are of gold standard in therapeutic applications. Due to the highest possibility of proper binding activity, the mammalian derived proteins are highly used for the production of monoclonal antibodies (MAB), clotting factors, and hormones.
The capability of mammalian cell cultures to synthesize large and complex protein molecules and high tolerance to environmental changes is high. Thus, Mouse myeloma and Chinese hamster ovary cell systems are conventionally used for producing mammalian derived proteins.
| Attributes | Details |
|---|---|
| Mammalian Derived Proteins Market Value in 2021 | USD 588.9 Million |
| Mammalian Derived Proteins Market Value in 2032 | USD 1.5 Billion |
| Mammalian Derived Proteins Market CAGR (2022 to 2032) | 9.0% |
The major factor driving the mammalian derived proteins market is rising prevalence of chronic diseases like cancer and cardiac disorders. This factor act as the biggest driver for the market. Additionally, the increase in the fertility problems has raised the adoption rate of hormonal therapies across the globe.
As most of the fertility hormones are developed through mammalian cell cultures, the global mammalian derived protein market is expected to propel in the near future.
Moreover, utilizing human cell lines for the production of mammalian derived proteins is popular in the industry. Technological advancements in genome engineering has developed different approaches of expression and isolation of proteins for research purpose. This will drive the mammalian derived proteins market in the projected period.
Owing to the technological development and premier research institutes in the U.S. and Canada, the North American region will lead the mammalian derived proteins market. Also, the growth of the mammalian derived proteins market will be triggered by the rising prevalence of chronic diseases along with the rising infertility issues among people in this region.
Following North America, Europe will lead the market to grow due to the increasing incidence of chronic illness and rising geriatric population. Additionally, strong investment in healthcare structure will boost the market for mammalian derived proteins in Europe. In East Asia, China is estimated to drive market growth with the rising prevalence of cardiovascular diseases.
Due to the less awareness among the population in the regions like Latin America, the Middle East, and Africa, the growth rate for the mammalian derived proteins market is low.
Some of the key manufacturers of mammalian derived proteins market are F. Hoffmann-La Roche Ltd, Merck KGaA, Eli Lilly and Company, Lonza., CUSABIO TECHNOLOGY LLC., Prospec-Tany Technogene Ltd., Randox Laboratories Ltd, Geno Technology Inc., Kaneka Eurogentec S.A., Batavia Biosciences., Abnova Corporation, Cayman Chemical, SOSV LLC – IndieBio, and Bioclone Inc.
| Report Attributes | Details |
|---|---|
| Growth Rate | CAGR of 9.0% 2022 to 2032 |
| Base Year for Estimation | 2021 |
| Historical Data | 2012 to 2021 |
| Forecast Period | 2022 to 2032 |
| Qualitative Units | Revenue in USD Million and CAGR from 2022 to 2032 |
| Report Coverage | Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis |
| Segment Covered |
Product, Therapy Area, Application, End User, Region |
| Region Covered |
North America; Latin America; Europe; East Asia; South Asia; Oceania; Middle East & Africa |
| Key Countries Profiled |
USA, Canada, Brazil, Mexico, Germany, UK, France, Spain, Italy, China, Japan, South Korea, Malaysia, Singapore, Australia, New Zealand, GCC, South Africa, Israel |
| Key Players |
F. Hoffmann-La Roche Ltd; Merck KGaA; Eli Lilly and Company; Lonza.; CUSABIO TECHNOLOGY LLC.; Prospec-Tany Technogene Ltd.; Randox Laboratories Ltd; Geno Technology Inc.; Kaneka Eurogentec S.A.; Batavia Biosciences.; Abnova Corporation; Cayman Chemical; SOSV LLC - IndieBio; Bioclone Inc |
| Customization | Available Upon Request |
The global mammalian derived proteins market is anticipated to register a CAGR of 9.0% during the forecast period.
The mammalian derived proteins market is projected to be about US$ 1.5 Bn by the end of year 2032.
Explore Similar Insights
Mammalian Derived Proteins Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
